Firstly, the effects of GLP-1 therapy on liver enzymes and the lipid profile in NAFLD were not the primary aim of the clinical trials and the studies were not powered for this. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.